Lornoxicam and puerarin eutectic crystal and preparation method thereof

A technology of lornoxicam and puerarin, applied in the field of medicine, can solve the problems of poor water solubility of lornoxicam and puerarin, poor compressibility of lornoxicam, etc., and achieve the effects of increasing solubility and improving compressibility

Active Publication Date: 2020-04-14
CHINA PHARM UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Purpose of the invention: the present invention provides a co-crystal of lornoxicam puerarin and a preparation method thereof, the co-crystal solves the problem of poor water solubility of lornoxicam and puerarin; poor problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lornoxicam and puerarin eutectic crystal and preparation method thereof
  • Lornoxicam and puerarin eutectic crystal and preparation method thereof
  • Lornoxicam and puerarin eutectic crystal and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0032] The preparation method of lornoxicam puerarin co-crystal:

[0033] Add 0.371g of lornoxicam and 0.434g of puerarin into a mixed solvent of 80mL of methanol and 120mL of chloroform, dissolve it to a clear liquid, evaporate it under reduced pressure at 30°C, dry it in vacuum at 20°C for 24h, and place it in a 155°C resistor The solvent was removed in the furnace for 2 minutes to obtain lornoxicam puerarin eutectic.

example 2

[0035] The preparation method of lornoxicam puerarin sodium salt complex:

[0036] Add 0.371g of lornoxicam and 0.434g of puerarin into a mixed solvent of 40mL of methanol and 160mL of chloroform, dissolve it to a clear liquid, evaporate it under reduced pressure at 55°C, dry it in vacuum at 25°C for 24h, and place it in a 165°C resistor The solvent was removed in the furnace for 2 minutes to obtain lornoxicam puerarin eutectic.

example 3

[0038] The preparation method of lornoxicam puerarin sodium salt complex:

[0039] Add 0.371g of lornoxicam and 0.434g of puerarin into a mixed solvent of 25mL of methanol and 175mL of chloroform, dissolve it to a clear liquid, evaporate it under reduced pressure at 80°C, dry it in vacuum at 35°C for 24h, and place it in a 175°C resistor The solvent was removed in the furnace for 2 minutes to obtain lornoxicam puerarin eutectic.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a lornoxicam and puerarin eutectic crystal, which is formed by combining lornoxicam and puerarin according to a molar ratio of 1: 1, and has a powder X-ray diffraction patternexpressed by a 2theta angle value, and an infrared spectrogram. The method comprises the following steps: dissolving the lornoxicam and the puerarin into an organic solvent according to a certain molar ratio, carrying out reduced pressure rotary evaporation on the solvent, carrying out vacuum drying, and putting into a resistance furnace to remove the solvent, thereby obtaining the lornoxicam andpuerarin eutectic crystal. The eutectic crystal is different from a lornoxicam monomer, a puerarin monomer and a physical mixture of the lornoxicam monomer and the puerarin monomer in powder X-ray diffraction and infrared ray, the crystal form of the eutectic crystal is a new crystal form different from the monomers and the physical mixture, and the compressibility of lornoxicam and the water solubility of the lornoxicam and the puerarin are improved.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to lornoxicam puerarin co-crystal and a preparation method thereof. Background technique [0002] Lornoxicam (Lornoxicam) belongs to the non-steroidal anti-inflammatory analgesics of the Xicam class. Its action sites are mainly in the central nervous system and peripheral pain areas. It has analgesic, anti-inflammatory and antipyretic effects. It is widely used clinically in rheumatic The treatment of diseases such as arthritis and rheumatoid arthritis occupies an important position in non-steroidal analgesic anti-inflammatory drugs, and has a good market development prospect. Its chemical name is 6-chloro-4-hydroxy-2-methyl-3-(2-pyridinecarbamoyl)-2H-thieno[2,3-e]-1,2-thiazine-1,1 - Dioxide, molecular formula C 13 h 10 ClN 3 o 4 S 2 , the structural formula is as follows: [0003] [0004] Puerarin is an isoflavone compound extracted from the dried roots of Pueraria loba...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D513/04C07D407/04
CPCC07B2200/13C07D407/04C07D513/04
Inventor 华韵骆敏倩薛一凡朱恒清程冉高缘张建军
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap